The discovery that threosyl phosphonate nucleoside (PMDTA, EC 50 = 2.53 µM) is a potent anti-HIV agent has led to the synthesis and biological evaluation of 5'-deoxy versions of threosyl phosphonate nucleosides. In the present study, (E)-3'-phosphonoalkenyl and 3'-phosphonoalkyl nucleoside analogues 13, 16, 20 and 23 were synthesized from acetol and tested for anti-HIV activity and cytotoxicity. The adenine analogue 16 was found to exhibit moderate in vitro anti-HIV-1 activity (EC 50 = 22.2 µM).
Introduction
Phosphorus-modified nucleoside analogues, bearing a phosphonate group in their sugar moiety, have shown potent antiviral activity. 1 Since antiviral activity is often associated with nucleoside analogues bearing a phosphonomethoxy group in the sugar moiety, comparatively little attention has been paid to the properties and scopes of other phosphonate functions in relationship to biological activity.
On the other hand, considerable attention has been paid to unusual nucleosides since modified nucleosides were reported to be promising anti-human immunodeficiency virus (HIV) and anti-hepatitis B virus (HBV) agents. Of these compounds, threose nucleosides, 2 such as, PMDTA (1) and PMDTT (2) , have been previously synthesized ( Figure  1 ) because they can be assembled from natural precursors. 3 Furthermore, it has been demonstrated that threose nucleic acids (TNA) form duplexes with DNA and RNA that are thermally stable, in an analogous manner to natural nucleic acid association. The triphosphates of threose nucleosides are substrates of several polymerases, and can be enzymatically incorporated into DNA. 4 Actually, these nucleosides are accepted as substitutes for ribonucleosides in the catalytic site of hammerhead ribozyme, although subsequently, the catalytic efficiency of the ribozyme is significantly reduced. 5 The phosphonoalkoxy group of the proposed threose nucleoside phosphonates is bound at the 3'-position, which brings the phosphorus atom and the nucleobase closer together than in previously synthesized nucleoside phosphonates, where the phosphonate group is bound to the primary hydroxyl group of the nucleoside.
In the literature, nucleoside phosphonates have been prepared from several 5'-phosphate isosteres. As shown in Figure 1 , compound 3 6 is a simple 5'-deoxynucleoside phosphonate, in which the 5'-oxygen of a nucleoside phosphate is replaced by a methylene (Figure 1 ). More recently, we synthesized the novel threosyl 5'-deoxynucleoside adenine phosphonate 4. 7 All phosphonates mimic the overall shape and geometry of nucleoside monophosphates.
Phosphorylation by kinases and the incorporation into nucleic acid (eventually leading to chain termination) is considered as important mechanism underlying the antiviral activities of nucleosides. In fact, lack of antiviral activity by a nucleoside phosphonate is generally attributed to poor substrate properties for cellular and viral kinases. On the other hand, the potent antiviral activities of phosphonylated alkylated nucleobases are ascribed to their intracellular phosphorylation to diphosphates and to refractory incorporation of the modified nucleosides in nucleic acids. 8 Furthermore, the enzymatic incorporation of phosphonate nucleosides into nucleic acids is almost irreversible, which is not the case for regular nucleotides.
Phosphonates have certain advantages over their phosphate counterparts because they are metabolically stable due to the lack of susceptibility of the phosphorus-carbon bond to hydrolytic cleavage. 9 Moreover, the spatial location of the carbon atom, namely the β-position from the phosphorus atom in the nucleoside analogue, has been demonstrated to play a critical role in antiviral activity. 10 The antiviral activities conferred by these atoms may be due to the increased binding capacity of the phosphonate analogues for target enzymes. 11 Encouraged by these findings that threosyl nucleoside analogues and 5'-deoxynucleoside phosphonates have excellent biological activities, we explored the antiviral activities conferred by removing the 5'-oxygen or replacing this oxygen with carbon moieties, which resulted in 5'-phosphonate derivatives, and we evaluated their activities against various viruses.
Results and Discussion
As shown in Scheme 1, target compounds were prepared from acetol via an acyclic synthesis route. 12 The lactone functional group of 7 was prepared via desilylation and cyclization from 6, and 7 was subsequently reduced using DIBALH in toluene at -78°C to give lactol 8, which was acetylated in pyridine to furnish the key intermediate 9 (a glycosyl donor) (Scheme 1). The synthesis of adenine nucleoside was carried out by condensation between 9 and silylated 6-chloropurine using TMSOTf as a catalyst in DCE to give the protected 6-chloropurine derivatives 10a and 10b, respectively. A complete NOE study allowed the unambiguous determination of their respective stereochemistries ( Figure 2 ). For compound 10b, strong NOE (0.7%) of H-1' ↔ CH-3', showing 1',3'-cis relationships, was observed. According to this result, the 3'-vinyl group and the 1'-purine base of 10b were located on the β face. On the other hand, for 10a, weak NOE (0.2%), such as, H-1' ↔ CH-3', were assigned to the 1',3'-trans relationship.
Cross-metathesis 13 of 10b with diethylphosphonate using 2 nd generation Grubbs catalyst 14 gave the vinylidene phos- phonate nucleoside analogue 11, the chlorine group of which was then converted to amine using methanolic ammonia at 60 o C to give the corresponding adenosine phosphonate derivative 12. Hydrolysis of the diethyl phosphonate functional groups of 12 with bromotrimethylsilane in CH 3 CN in the presence of 2,6-lutidine then gave the adenosine phosphonic acid derivative 13. 15 The vinylidene phosphonate of 13 was then saturated under transfer catalytic hydrogenation conditions to give the ethyl phosphonate nucleoside analogue 14. Adenine analogue 16 was prepared using reaction conditions (ammonolysis and hydrolysis) similar to those described to prepare 13.
To synthesize guanine analogues, 2-fluoro-6-chloropurine 16 was condensed with glycosyl donor using conditions similar to those used for the condensation of 6-chloropurine. Vorbruggen coupling 17 of the acetate 9 with 2-fluoro-6chloropurine provided the analogues 17a (32%) and 17b (33%). Cross-metathesis of 17b and diethylvinylphosphonate then produced 18 at a yield of 59%.
Bubbling ammonia into compound 18 provided the two separable analogues 2-fluoro-6-aminopurine 18 19a (16%) and 2-amino-6-chloropurine 19b (46%). Fluorine atom acts as a good leaving group than chlorine atom in nucleophilic aromatic substitution. The 2-amino-6-chloropurine derivative 19b was treated with TMSBr to provide phosphonic acid, and then treated with sodium methoxide and 2-mercaptoethanol in methanol to give the desired guanine vinylidene phosphonic acid 20 (Scheme 2). 19 The guanine phosphonate 23 was synthesized from 18 by transfer catalytic hydrogenation and by ammonolysis and hydrolysis using conditions similar to those described for the synthesis of 20.
The antiviral activity of phosphonate nucleosides is largely due to their intracellular conversions to diphosphates, their subsequent incorporation into the viral genome, and chain termination. 20 The synthesized compounds 13, 16, 20, and 23 were tested against HIV-1 and for cytotoxicity using AZT and PMEA as positive controls; results are summarized in Table 1 . Anti-HIV activity was determined in human peripheral blood mononuclear (PBM) cells infected with HIV-1 strain LAI. In particular, the adenine analogue 16 show moderate antiviral activity against HIV-1, indicating that this virus might allow the sugar moiety for diphosphorylation or some affinity of its diphosphate toward viral polymerases. PBM cells (1 × 10 5 cell/mL) were infected with HIV-1 at a multiplicity of infection (MOI) of 0.02 and cultured in the presence of various concentrations of the test compounds. After 4 days of incubation at 37 o C, numbers of viable cells were determined using the 3-(4,5-di-methylthiazole-2-yl)-2,5-diphenyltetrazolium bromide method. The cytotoxicities of the compounds were evaluated in parallel with their antiviral activities, which were assessed based on the viabilities of mock-infected cells. 21 
Conclusion
In summary, based on the known potent anti-HIV activities of threosyl 5'-norcarbocyclic nucleoside analogues, we designed and successfully synthesized novel 5'-deoxyphosphonate nucleoside analogues starting from acetol. The previously synthesized adenine 4 exhibited better cell-based activity than 4'-methyl branched adenine phosphonic acid 16, which suggests that the methyl substituent at the 4'position is possibly responsible for the apparent lack of activity of 16. Superimposed modeling of PMDTA and 16 highlighted differences in adenine bases and phosphonic acid moieties (Figure 3 ). 22 
Experimental Section
Melting points were determined on a Mel-temp II laboratory device and were not corrected. NMR spectra were recorded on a JEOL 300 Fourier transform spectrometer (JEOL, Tokyo, Japan); chemical shifts are reported in parts per million (δ) and signals are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and dd (doublet of doublets). UV spectra were obtained using a Beckman DU-7 spectrophotometer (Beckman, South Pasadena, CA, USA). MS spectra were collected in electrospray ionization (ESI) mode. The elemental analyses were performed using a Perkin-Elmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA). TLC was performed on Uniplates (silica gel) purchased from Analtech Co. (7558, Newark, DE, USA). All reactions were carried out under a nitrogen atmosphere unless otherwise specified. Dry dichloromethane, benzene, and pyridine were obtained by distillation from CaH 2 . Dry THF was obtained by distillation from Na and benzophenone immediately prior to use.
(±)-3-Methyl-3-vinyl-dihydrofuran-1-one (7) . To a solution of 6 (1.2 g, 4.19 mmol) in THF (10 mL), TBAF (5.03 mL, 1.0 M solution in THF) was added at 0 o C. The mixture was stirred overnight at rt and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc, 10:1) to give 7 (375 mg, (±)-Acetic acid 3-methyl-3-vinyl-tetrahydrofuran-1-yl ester (9) . To a solution of compound 8 (151 mg, 1.18 mmol) in anhydrous pyridine (8 mL), Ac 2 O (0.177 g, 1.75 mmol) was slowly added, and the mixture was then stirred overnight under nitrogen. The pyridine was then evaporated under reduced pressure and co-evaporated with toluene, and the residue so obtained was diluted with H 2 O (50 mL), extracted with EtOAc (60 mL), dried over MgSO 4 , and filtered. The filtrate was then concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (EtOAc/hexane, 1:20) to give compound 9 (170 mg, 85%) as a colorless oil: 1 H NMR (CDCl 3 , 300 MHz) δ 6.25-6.20 (m, 1H), 5.71-5.67 (m, 1H), 5.04-4.95 (m, 2H), 3.73-3.70 (m, 2H), 2.06-2.00 (m, 2H), 2.03 (s, 3H), 1.24 (s, 3H).
(rel)-(1'R,3'R)-9-(3'-Methyl-3'-vinyl-tetrahydrofuran-1'-yl) 6-chloropurine (10a) and (rel)-(1'S,3'R)-9-(3'methyl-3'-vinyl-tetrahydrofuran-1'-yl) 6-chloropurine (10b). 6-Chloropurine (158 mg, 1.027 mmol), anhydrous HMDS (8 mL), and a catalytic amount of ammonium sulfate (12 mg) were refluxed to provide a clear solution, and the solvent was then distilled under anhydrous conditions. The residue so obtained was dissolved in anhydrous 1,2dichloroethane (8 mL), and a solution of 9 (102 mg, 0.6 mmol) in dry DCE (10 mL) and TMSOTf (228 mg, 1.027 mmol) was added and stirred for 8 h at rt. The reaction mixture was then quenched with 2.5 mL of saturated NaHCO 3 and stirred for 1 h, and the resulting solid was filtered through a Celite pad. The filtrate was extracted with CH 2 Cl 2 twice, and combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (EtOAc/hexane, 4:1) to give compounds 10a (52 mg, 33%) and 10b (54 mg, 34%). Data for 10a: 1 H NMR ( (rel)-(1'R,3'R)-9-(3'-Methyl-3'-vinyl-tetrahydrofuran-1'-yl) adenine}phosphonic acid (13) . To a solution of the phosphonate 12 (153 mg, 0.403 mmol) in anhydrous CH 3 CN (10 mL) and 2,6-lutidine (0.938 mL, 8.06 mmol) was added trimethylsilyl bromide (0.616 mg, 4.03 mmol). The mixture was heated overnight at 70 o C under nitrogen and then concentrated in vacuo. The residue obtained was partitioned between CH 2 Cl 2 (100 mL) and purified water (100 mL), and the aqueous layer was washed with CH 2 Cl 2 (2 × 70 mL) and then freeze-dried to give phosphonic acid 13 (97 mg, 74%) as a yellowish foam: UV (H 2 O) λ max 261. (rel)-(1'R,3'R)-Diethyl {9-(3'-methyl-3'-ethyltetrahydrofuran-1'-yl) 6-chloropurine} phosphonate (14) . A solution of vinyl phosphonate nucleoside analogue 11 (320 mg, 0.798 mmol) in methanol (15 mL) was added to 10% Pd/C (10 mg) in cyclohexene (5 mL) under Ar. The reaction mixture was refluxed for 25 h, and then filtered through a pad of Celite, evaporated, and purified by silica gel column chromatography using methanol and methylene chloride (rel)-(1'R,3'R)-Diethyl {9-(3'-methyl-3'-ethyltetrahydrofuran-1'-yl) adenine} phosphonate (15) . The adenine derivative 15 was prepared from the 6-chloropurine analogue 14 using an ammonolysis procedure similar to that described for 12: yield 58%; mp 167-169 ºC; UV (MeOH) λ max 262. 
